Bladder Cancer Detection Kit Market Size was valued at USD 0.111 billion in 2023. The bladder cancer detection kit market industry is projected to grow from USD 0.123 billion in 2024 to USD 0.264 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.94% during the forecast period (2024 - 2032). The key market drivers that are driving the growth include the rising incidence of bladder cancer, greater public knowledge of cancer and its treatments, rising healthcare costs, and rising cigarette and tobacco use.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The World Cancer Research Fund (WCRF) estimates that roughly 275,000 individuals worldwide are diagnosed with bladder cancer each year, and that 108,000 people worldwide pass away from bladder cancer. Additionally, bladder cancer is the sixth most prevalent disease in men and the 17th most prevalent cancer in women worldwide. Men's bladder cancer incidence rates per 100,000 people were greatest in Greece in 2018 at 40.4%, followed by Lebanon at 40.0% and Denmark at 29.3%. The greatest incidence for females was 9.4 per 100,000 people in Lebanon. The need for a bladder cancer diagnosis is growing as its prevalence and fatality rate are rising globally. As a result, the market CAGR for bladder cancer detection kits is growing as more money is invested in R&D of non-invasive bladder cancer detection technologies.
Over the course of the forecast period, the market is expected to be driven by a number of strategies used by the major market competitors, including product releases and mergers and acquisitions. For example, Merck, known as MSD outside of the United States and Canada, reported a label update for KEYTRUDA, Merck's anti-PD-1 therapy, in first-line advanced urothelial carcinoma (bladder cancer) in the United States in August 2021.
Furthermore, the market for bladder cancer detection kits may experience rapid expansion as a result of rising healthcare costs, expanding burden of bladder cancer, and rising knowledge of bladder diseases and treatments. For instance, the World Bladder Cancer Patient Coalition has declared March 2022 to be "Don't Go Red" Month for Bladder Cancer knowledge in an effort to increase public knowledge of the disease's warning signs and symptoms. Early detection is essential for improving long-term survival and quality of life. Thus, driving the bladder cancer detection kit market revenue.
The bladder cancer detection kit market segmentation, based on technology includes Fluorescence In Situ Hybridization (FISH), Enzyme-Linked Immunosorbent Assay (ELISA), and Others. The fluorescence in situ hybridization (FISH) segment dominated the market. To replace cystoscopy in the field of urology, this technology offers a non-invasive diagnostic application. In urology, hybridization is used in in situ fluorescence, a non-invasive diagnostic alternative to cystoscopy. Due to the innovative urine examination technique used in this segment, which uses fluorescent direct-tagged DNA probes to identify genetic abnormalities in urothelial cells found in the urine, this segment is anticipated to take the lead.
Figure 1: Bladder Cancer Detection Kit Market, by Technology, 2023 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The bladder cancer detection kit market segmentation, based on end users, includes Hospitals & Clinics, Diagnostic Centers, Others. The hospitals & clinics category generated the most income. The bladder cancer detection kit market is being driven by innovations in hospital infrastructure across the globe. Investors are utilizing the bladder cancer market to build cancer detection and treatment hospitals. Additionally, the investor constructing hospitals for cancer diagnosis and treatment uses the bladder cancer market.
Bladder Cancer Detection kit Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American bladder cancer detection kit market area will dominate this market. The market for bladder cancer detection kits in North America is driven primarily by the increased prevalence of bladder cancer in the region. The American Cancer Society estimates that in the US in 2020, there will be around 83,730 new cases of bladder cancer and about 17,200 bladder cancer fatalities. Additionally, it is projected that greater government initiatives, improved healthcare infrastructure, and increased R&D spending would all promote the growth of the bladder cancer detection kit market in these regions.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: BLADDER CANCER DETECTION KIT MARKET SHARE BY REGION 2022 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe bladder cancer detection kit market accounts for the second-largest market share as the demand for bladder cancer detection is rising due to the increased prevalence and fatality rate in this region. The market for bladder cancer detection kits is also growing as a result of increased investment in R&D of non-invasive bladder cancer detection kits. Further, the German bladder cancer detection kit market held the largest market share, and the UK bladder cancer detection kit market was the fastest growing market in the European region
The Asia-Pacific Bladder cancer detection kit Market is expected to grow at the fastest CAGR from 2024 to 2032. The market for bladder cancer detection kit is expanding as a result of the rising incidence of bladder cancer in the elderly and the growing old population in Asia-Pacific. According to Globocan, the ageing population is the main factor contributing to the rise in bladder cancer occurrences in Japan, where it is estimated that 37,000 new cases are identified each year and 11,000 people die from the disease. Moreover, China’s bladder cancer detection kit market held the largest market share, and the Indian bladder cancer detection kit market was the fastest growing market in the Asia-Pacific region.
Bladder Cancer Detection Kit Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the bladder cancer detection kit market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, bladder cancer detection kit industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the bladder cancer detection kit industry to benefit clients and increase the market sector. In recent years, the bladder cancer detection kit industry has offered some of the most significant advantages to medicine. Major players in the bladder cancer detection kit market attempting to increase market demand by investing in research and development operations include Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain) and Xiamen Boson Biotech Co., Ltd (China).
Abbott Laboratories (Abbott) researches, develops, produces, and markets a wide variety of healthcare goods, including branded generic medications, diagnostic tools, and infant, adolescent, and adult nutritional supplements. The company also sells a range of medical devices, such as those for neuromodulation, electrophysiology, rhythm control, vascular and structural cardiac devices, and heart failure. Additionally, the business sells dietary supplements, minerals, and nutrition goods.
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic firm that focuses on the creation of assays for various cancer kinds. Cologuard test, the company's main product, is a non-invasive stool-based deoxyribonucleic acid (DNA) screening tool authorized by the US FDA for early colorectal cancer and pre-cancer detection. It employs a multi-target strategy to find DNA and hemoglobin biomarkers associated with colorectal cancer. In addition, the business provides Oncotype DX gene expression tests for colon, breast, and prostate cancers, as well as Oncotype DX AR-V7 Nucleus Detect, a liquid-based test intended for advanced-stage prostate cancer.
Key Companies in the bladder cancer detection kit market include
May 2021:To create the non-invasive bladder cancer test URO17, KDx Diagnostics (US) partnered with Cardiff University, the Cardiff and Vale University Health Board, or C&VUHB, and CellPath.
March 2021:For the purpose of commercializing its Urodiag PCR-based diagnostic test for recurring bladder cancer in France, the OncoDiag company, based in France, raised USD 3.0 million.
Fluorescence In Situ Hybridization (FISH)
Enzyme-Linked Immunosorbent Assay (ELISA)
Others
Hospitals & Clinics
Diagnostic Centers
Others
Bladder Cancer Detection Kit Regional Outlook
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.111 billion |
| Market Size 2024 | USD 0.123 billion |
| Market Size 2032 | USD 0.264 billion |
| Compound Annual Growth Rate (CAGR) | 9.94% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Technology, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Diagnosis S.A. (Spain) and Xiamen Boson Biotech Co., Ltd (China) |
| Key Market Opportunities | Emergence of new products |
| Key Market Dynamics | Increasing prevalence of bladder cancer |
Bladder Cancer Detection Kit Market Highlights:
Frequently Asked Questions (FAQ) :
The bladder cancer detection kit market size was valued at USD 0.111 Billion in 2023.
The market is projected to grow at a CAGR of 9.94% during the forecast period, 2024-2032.
North America had the largest share in the market
The key players in the market are Abbott Laboratories (US), Xiamen Biotime Biotechnology (China), Exact Sciences (US), Hubei Jinjian Biology (China), Nanjing Liming Bio-products Co., Ltd (China), Abingdon Health (UK), Ameritek, Inc. (US), Alfa Scientific Designs (US), NanoEnTek Inc. (South Korea), Diagnosis S.A. (Spain) and Xiamen Boson Biotech Co., Ltd (China).
The Fluorescence In Situ Hybridization (FISH) category dominated the market in 2022.
The hospitals & clinics category had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
